Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer

Inclusion Criteria: * The patient must be ≥ 18 years old at the time of signing the ICF. * The patient must have a histologically proven adenocarcinoma of the colon or rectum. * The patient must have liver metastases non treatable with curative intent by surgical resection or local ablation at the time of registration. * The patient must have measurable hepatic metastases defined by RECIST version 1.1 for solid tumors. * The patient must have received one prior chemotherapy line for metastatic disease and have developed resistance or intolerance to this treatment. * The patient must have an ECOG performance status 0 or 1. * The patient must have the bone marrow reserve, hepatic and renal functions Exclusion Criteria: * Patients who are presenting evidence of ascites, cirrhosis, portal hypertension, main portal venous tumor involvement or thrombosis as determined by clinical or radiologic assessment. * Patients who are planned to receive or concurrently receiving any non-cancer-directed investigational agent, or have received a non-cancer directed investigational agent within 3 weeks before the planned day for the first NKR-2 administration. * Patients who are scheduled to receive concurrent growth factor (except erythropoietin), systemic steroid, other immunosuppressive therapy or cytotoxic agents (systemic or localized) other than the treatment authorized per protocol. * Patients who underwent major surgery within 4 weeks before the planned day for the first NKR-2 administration. * Patients who have received a live vaccine ≤ 6 weeks prior to the planned day for the first NKR-2 administration. * Patients with a family history of congenital or hereditary immunodeficiency. * Patients with history of any autoimmune disease.